vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and STURM RUGER & CO INC (RGR). Click either name above to swap in a different company.
STURM RUGER & CO INC is the larger business by last-quarter revenue ($151.1M vs $139.2M, roughly 1.1× ADMA BIOLOGICS, INC.). On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 3.6%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $12.3M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 5.1%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Sturm, Ruger & Company, Inc., better known by the shortened name Ruger, is an American firearm manufacturing company based in Southport, Connecticut, with production facilities also in Newport, New Hampshire; Mayodan, North Carolina; and Prescott, Arizona. The company was founded in 1949 by Alexander McCormick Sturm and William B. Ruger and has been publicly traded since 1969.
ADMA vs RGR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $151.1M |
| Net Profit | $49.4M | — |
| Gross Margin | 63.8% | 17.8% |
| Operating Margin | 45.1% | 2.3% |
| Net Margin | 35.5% | — |
| Revenue YoY | 18.4% | 3.6% |
| Net Profit YoY | -55.9% | — |
| EPS (diluted) | $0.20 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $151.1M | ||
| Q3 25 | $134.2M | $126.8M | ||
| Q2 25 | $122.0M | $132.5M | ||
| Q1 25 | $114.8M | $135.7M | ||
| Q4 24 | $117.5M | $145.8M | ||
| Q3 24 | $119.8M | $122.3M | ||
| Q2 24 | $107.2M | $130.8M | ||
| Q1 24 | $81.9M | $136.8M |
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $1.6M | ||
| Q2 25 | $34.2M | $-17.2M | ||
| Q1 25 | $26.9M | $7.8M | ||
| Q4 24 | $111.9M | — | ||
| Q3 24 | $35.9M | $4.7M | ||
| Q2 24 | $32.1M | $8.3M | ||
| Q1 24 | $17.8M | $7.1M |
| Q4 25 | 63.8% | 17.8% | ||
| Q3 25 | 56.3% | 15.1% | ||
| Q2 25 | 55.1% | 3.9% | ||
| Q1 25 | 53.2% | 22.0% | ||
| Q4 24 | 53.9% | 22.8% | ||
| Q3 24 | 49.8% | 18.5% | ||
| Q2 24 | 53.6% | 22.3% | ||
| Q1 24 | 47.8% | 21.5% |
| Q4 25 | 45.1% | 2.3% | ||
| Q3 25 | 38.0% | -2.7% | ||
| Q2 25 | 35.1% | -15.6% | ||
| Q1 25 | 30.4% | 6.2% | ||
| Q4 24 | 32.6% | 7.8% | ||
| Q3 24 | 33.1% | 3.1% | ||
| Q2 24 | 36.6% | 6.9% | ||
| Q1 24 | 26.7% | 5.5% |
| Q4 25 | 35.5% | — | ||
| Q3 25 | 27.1% | 1.2% | ||
| Q2 25 | 28.1% | -13.0% | ||
| Q1 25 | 23.4% | 5.7% | ||
| Q4 24 | 95.2% | — | ||
| Q3 24 | 30.0% | 3.9% | ||
| Q2 24 | 29.9% | 6.3% | ||
| Q1 24 | 21.7% | 5.2% |
| Q4 25 | $0.20 | $0.22 | ||
| Q3 25 | $0.15 | $0.10 | ||
| Q2 25 | $0.14 | $-1.05 | ||
| Q1 25 | $0.11 | $0.46 | ||
| Q4 24 | $0.45 | $0.62 | ||
| Q3 24 | $0.15 | $0.28 | ||
| Q2 24 | $0.13 | $0.47 | ||
| Q1 24 | $0.08 | $0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $92.5M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $283.8M |
| Total Assets | $624.2M | $342.0M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $92.5M | ||
| Q3 25 | $61.4M | $80.8M | ||
| Q2 25 | $90.3M | $101.4M | ||
| Q1 25 | $71.6M | $108.3M | ||
| Q4 24 | $103.1M | $105.5M | ||
| Q3 24 | $86.7M | $96.0M | ||
| Q2 24 | $88.2M | $105.6M | ||
| Q1 24 | $45.3M | $115.3M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $283.8M | ||
| Q3 25 | $431.2M | $279.6M | ||
| Q2 25 | $398.3M | $289.3M | ||
| Q1 25 | $373.4M | $321.5M | ||
| Q4 24 | $349.0M | $319.6M | ||
| Q3 24 | $231.9M | $314.9M | ||
| Q2 24 | $188.3M | $321.5M | ||
| Q1 24 | $153.7M | $332.0M |
| Q4 25 | $624.2M | $342.0M | ||
| Q3 25 | $568.7M | $342.3M | ||
| Q2 25 | $558.4M | $349.5M | ||
| Q1 25 | $510.6M | $379.0M | ||
| Q4 24 | $488.7M | $384.0M | ||
| Q3 24 | $390.6M | $373.5M | ||
| Q2 24 | $376.4M | $376.7M | ||
| Q1 24 | $350.9M | $385.0M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $15.5M |
| Free Cash FlowOCF − Capex | $34.6M | $12.3M |
| FCF MarginFCF / Revenue | 24.8% | 8.2% |
| Capex IntensityCapex / Revenue | 0.8% | 2.1% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $38.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $15.5M | ||
| Q3 25 | $13.3M | $12.9M | ||
| Q2 25 | $21.1M | $14.7M | ||
| Q1 25 | $-19.7M | $11.1M | ||
| Q4 24 | $50.2M | $20.0M | ||
| Q3 24 | $25.0M | $9.4M | ||
| Q2 24 | $45.6M | $18.7M | ||
| Q1 24 | $-2.2M | $7.3M |
| Q4 25 | $34.6M | $12.3M | ||
| Q3 25 | $-1.1M | $7.0M | ||
| Q2 25 | $18.7M | $9.1M | ||
| Q1 25 | $-24.4M | $10.0M | ||
| Q4 24 | $47.5M | $16.4M | ||
| Q3 24 | $24.0M | $2.6M | ||
| Q2 24 | $43.6M | $10.1M | ||
| Q1 24 | $-4.6M | $5.6M |
| Q4 25 | 24.8% | 8.2% | ||
| Q3 25 | -0.8% | 5.5% | ||
| Q2 25 | 15.3% | 6.9% | ||
| Q1 25 | -21.2% | 7.4% | ||
| Q4 24 | 40.4% | 11.2% | ||
| Q3 24 | 20.0% | 2.1% | ||
| Q2 24 | 40.7% | 7.7% | ||
| Q1 24 | -5.6% | 4.1% |
| Q4 25 | 0.8% | 2.1% | ||
| Q3 25 | 10.7% | 4.6% | ||
| Q2 25 | 2.0% | 4.2% | ||
| Q1 25 | 4.1% | 0.8% | ||
| Q4 24 | 2.3% | 2.5% | ||
| Q3 24 | 0.9% | 5.5% | ||
| Q2 24 | 1.9% | 6.6% | ||
| Q1 24 | 2.9% | 1.3% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | 8.15× | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | 1.43× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | 1.98× | ||
| Q2 24 | 1.42× | 2.27× | ||
| Q1 24 | -0.12× | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
